Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q3 2025 · 10-Q
Revenue$33.99M$33.99M+32.9% vs Q3 2024 Net Income$4.58M$4.58M+143.8% vs Q3 2024 EPS Diluted$0.05$0.05+150.0% vs Q3 2024 Gross Profit$21,928,000+35.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Operating Cash Flowderived$3,692,000+5.6% Margins · derivedGross margin64.5%+1.0 pt vs Q3 2024
Operating margin12.5%+6.2 pt vs Q3 2024
Net margin13.5%+6.1 pt vs Q3 2024
ended Sep 30, 2025 · filed Nov 4, 2025 · 35 d after period end